Project Grant K99ES036286
Award Date
8/16/24
Completion Date
7/31/26
Dollars Obligated
$124K
Federal Agency
National Institute of Environmental Health Sciences
Federal Grant Program
93.113
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40202, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop novel therapies for advanced metastatic triple-negative breast cancer (TNBC). The $622,329 award to Virginia Commonwealth University aims to modulate the growth, progression, and metastasis of TNBC by inhibiting the MDA-9 protein. Key objectives include: 1) formulating an MDA-9 inhibitor called PDZ1I for clinical use and characterizing its effects on the immune...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program will support research at the University of Alabama at Birmingham (UAB) to investigate the role of the PDZ binding kinase (PBK) in driving triple-negative breast cancer (TNBC) tumor growth and metastasis. The total funding for this 2-year project is $148,500, with a start date of July 1, 2024. The research aims to determine the in vivo effects of genetically or...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $647,118 to support research on the role of the EYA3 transcription coactivator and its interaction with PP2A in mediating metastasis of triple negative breast cancer (TNBC). The research, conducted by the University of Colorado-Denver, aims to determine the molecular and cellular mechanisms by which the EYA3-NF-kB axis enhances TNBC metastasis, and to elucidate how EYA3...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $631,492.00 to The University of Kentucky Research Foundation to identify and target the NNMT molecule as a novel therapy for treating triple-negative breast cancer (TNBC). The overarching goal is to define how NNMT promotes TNBC survival and metastasis, evaluate potent and specific NNMT inhibitors, and determine NNMT's therapeutic potential in preclinical TNBC models. The award,...
This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
This Project Grant award, titled "TARGETING METABOLIC VULNERABILITIES OF TRIPLE NEGATIVE BREAST CANCER STEM CELLS," is funded by the National Cancer Institute (CFDA Program 93.395 - Cancer Treatment Research). The $474,547 grant will support research by the Regents of the University of Michigan to investigate novel therapeutic approaches for targeting cancer stem-like cells in triple negative breast cancer (TNBC), an aggressive cancer subtype with few treatment options. The research...
This federal Project Grant award of $763,895 from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports research to understand the complex associations between environmental exposures, social determinants of health, and mammographic features predictive of breast cancer risk. The research team, led by investigators at the Harvard T.H. Chan School of Public Health and Brigham & Women's Hospital, will collect and analyze...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $304,158 to the University of Washington to conduct research on quantifying tumor heterogeneity in triple-negative breast cancer (TNBC) using advanced medical imaging techniques. The goal is to identify imaging-derived biomarkers that can predict treatment response and outcomes for TNBC patients. The research will involve retrospectively analyzing multiparametric MRI data to...
This Project Grant award of $1,058,750.00 from the National Institute on Minority Health and Health Disparities (NIMHD) under the Minority Health and Health Disparities Research (CFDA 93.307) program aims to investigate the role of mitochondrial DNA (mtDNA) alterations in triple-negative breast cancer (TNBC) racial disparities. The key objectives are to: Examine the pattern of a pre-optimized panel of 11 mtDNA mutations in European American (EA) and African American (AA) TNBC samples to validate...
This Project Grant award of $226,504 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The research aims to comprehensively understand the functional state of B and T cells, as well as mutant/tumor cells, in a mouse model of TNBC during both pre-malignant and malignant stages. Additionally, the study plans to gain...